GLP1R and type 2 diabetes mellitus: In a population-based cohort study (1), Dong et al. assessed the comparative cardiovascular effectiveness of sodium-glucose cotransporter 2 inhibitors (SGLT2is) vs. glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D) according to baseline status of cardio-renal disease.